Colorectal Cancer

In season 4, episode 18 of Targeted Talks, Arvind Dasari, MD, MS, dives into the recent approval of fruquintinib for patients with metastatic colorectal cancer.

The multicenter, open-label, CodeBreaK 300 trial of sotorasib plus panitumumab showed consistent efficacy across key subgroups of patients with metastatic colorectal cancer harboring KRAS G12C mutations.

While a notable difference in the occurrence of adverse events was seen between patients treated with maximal tumor debulking and standard systemic therapy vs systemic therapy alone, health-related quality-of-life and fatigue scales showed no substantial differences over time.

Researchers identified different functions of groups of intraepithelial T cells (T-IELs) throughout the gastrointestinal tract, which could help inform future immunological treatment for patients with colorectal cancer.

The treatment landscape for patients with resected stage III colon cancer has undergone a significant change, following publication of an International Development and Education Award presentation abstract in the August 2023 Journal of the National Comprehensive Cancer Network.

The CRCdx RAS mutation detection kit was designed to detect 35 variants of KRAS and NRAS exon 2, 3, and 4 somatic mutations in patients with colorectal cancer.

Fam-trastuzumab deruxtecan-nxki was granted 2 breakthrough therapy designations by the FDA for its potential to fill a treatment gap for HER2-expressing tumors.

Treatment with an investigational mitochondrial inhibitor and bevacizumab has started in a phase 1b clinical trial of patients with previously-treated metastatic colorectal cancer.

Trifluridine/tipiracil plus bevacizumab improved rates of progression-free and overall survival vs trifluridine/tipiracil alone in the SUNLIGHT study. Now, the combination is FDA-approved for patients with metastatic colorectal cancer.

Following early efficacy demonstrated with DKN-01, bevacizumab, and chemotherapy in part A of the DeFianCe study, part B has begun enrolling patients with advanced colorectal cancer.

The combination of botensilimab and balstilimab combination showed a survival benefit, regardless of RECIST 1.1 responses, among patients with metastatic, heavily pretreated, microsatellite stable colorectal cancer.

The FoundationOne®Liquid CDx has received FDA approval as a companion diagnostic for encorafenib plus cetuximab for patients with BRAF V600E-mutated metastatic colorectal cancer.

The primary end point was not reached in the phase 3 SOLSTICE study.

Results from the DESTINY-CRC02 study showed that a lower dose of trastuzumab deruxtecan elicited promising results for patients with HER2-positive metastatic colorectal cancer vs a higher dose of the therapy.

In an interview with Targeted Oncology, Narissa Nonzee, PhD, discussed a study which focused on increasing colorectal screening rates among patients in ethnic minority communities.

Tanios S. Bekaii-Saab, MD, FACP, discusses the patient population, methods, and design utilized in the phase 3 MOUNTAINEER-03 study.

If granted approval, fruquintinib will be the first and only highly selective inhibitor of all 3 VEGF receptors to be approved in the United States for patients with metastatic colorectal cancer.

Oncologists are seeing early onset colorectal cancer more frequently, according to Jalal S. Baig, MD, medical oncologist at City of Hope Chicago.

DKN-01, an anti-DKK1 antibody, is being evaluated with bevacizumab and chemotherapy for patients with advanced colorectal cancer in the phase 2 DeFianCe trial.

Studies have increasingly supported the use of total neoadjuvant therapy, moving chemotherapy use ahead of surgical resection of rectal tumors.

The combination of botensilimab and balstilimab is moving down the FDA pipeline and may become an approved treatment for non-microsatellite instability-high and deficient mismatch repair metastatic colorectal cancer in the future.

The FDA plans to conduct a speedy review of an approval application for trifluridine plus tipiracil and bevacizumab for the treatment of metastatic colorectal cancer.

In an interview with Targeted Oncology, Olumide B. Gbolahan, MBBS, MSc, commented on studies that support the use of ctDNA to guide treatment decisions in the adjuvant setting for patients with colorectal cancer.

Neither the LEAP-003 nor LEAP-017 studies study showed survival benefit with pembrolizumab plus lenvatinib for patients with melanoma or colorectal cancer.

Soon, the FDA will be considering fruquintinib for approval to treat patients with refractory metastatic colorectal cancer.